News
2021
-
-
Sysmex and Yamato Transport Commence Dry Ice-Free Transportation of Reagents for Gene Testing in Consolidated Cargo at the Ultralow Temperature Range of Minus 70 Degrees Celsius
- Realizing an Eco-Friendly, Low-Cost, and Sustainable Pharmaceutical Product Cold Chain - (PDF：300KB)
-
-
Information about Litigation (Appeal) against Sysmex Corporation and its Subsidiary (PDF：135KB)
-
-
Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2022 (PDF：441KB)
-
-
Announcement Regarding Differences between Actual and Forecast Figures for the Six Months Ended September 30, 2021, and Revision of Full-Year Financial Forecasts (PDF：184KB)
-
-
Notice of Application for Selection of New Market Segment “Prime Market” on the Tokyo Stock Exchange (PDF：141KB)
-
-
Sysmex Launches Caresphere™ XQC, an External Quality Assessment App
- Enhancing the Reliability of Testing Results and Efficiency of Laboratory Operations with the Expansion of Caresphere - (PDF：165KB)
-
-
Sysmex Starts Implementing Job-Based HR Management System for All Employees (PDF：149KB)
-
-
Notice Concerning Absorption-Type Merger (Simplified/Short-Form Merger) of Wholly Owned Subsidiary (PDF：234KB)
-
-
Approval of "Genetic Diagnosis and Counseling for Inherited Retinal Dystrophy" Using Gene Panel Testing System for Advanced Medical Care B (PDF：202KB)
-
-
Information about Judgment of the Litigation against Sysmex Corporation and its Subsidiary (PDF：132KB)
-
-
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2022
-
-
Sysmex Forms Strategic Alliance with QIAGEN for Providing Global Cancer Companion Diagnostics that Uses Ultra-sensitive Liquid Biopsy NGS Technology (PDF：205KB)
-
-
Our Views and Policy regarding Investment Unit Reduction (PDF：94KB)
-
-
Sysmex Obtains IVDR Certification for LYNOAMP™ CK19 E, a Gene Amplification Detection Reagent
- Prompt response to legislative changes in the European region that demand greater product safety - (PDF：184KB)
-
-
Th2 Chemokine TARC Kit "HISCL™ TARC Assay Kit" is Approved for an Additional Indication as an Auxiliary for Assessment of COVID-19 Aggravation risk (PDF：210KB)
-
-
SARS-CoV-2 antibody status in patients with cancer during the COVID-19 pandemic in Japan (PDF：205KB)
-
-
Sysmex Relocates its PCR Testing Laboratory to its Research and Development Center for Expanded Functions (PDF：154KB)
-
-
Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2021
-
-
Sysmex Announces Changes from Financial Forecasts and Year-End Dividend for the Fiscal Year Ended March 31, 2021 (PDF：174KB)
-
-
Announcement of Executive Change (PDF：176KB)
-
-
Sysmex Announces New Group Mid-Term Management Plan
- Harnessing Groupwide Capabilities and Promoting Corporate Reforms with a View to Sustainable Growth - (PDF：210KB)
-
-
Sysmex and ThinkCyte Agree on Joint Development and Capital Alliance
- Commencing development of novel AI-based cell analyzers and testing techniques - (PDF：255KB)
-
-
Sysmex Obtains Manufacturing and Marketing Approval for Novel Coronavirus Detection Reagent (RT-PCR Method)
- Building a Self-Sufficient Production System in Japan for a Stable Supply of PCR Testing Kits - (PDF：169KB)
-
-
Sysmex Continues to Evolve Its Hematology Product Portfolio
- Flagship Model XR-Series and Compact 3-part WBC Differential Model XQ-Series to Be Rolled Out Sequentially - (PDF：209KB)
-
-
Announcement of Organizational and Personnel Changes (PDF：385KB)
-
-
Sysmex Presents Academic Report on Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
- Presenting the Most Recent Data at the 15th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2021) - (PDF：118KB)
-
-
Sysmex Obtains Manufacturing and Marketing Approval for an Influenza A/B Virus Antigen Detection Test Kit
Influenza can be simultaneously measured in a short period of time in the same the novel coronavirus (SARS-CoV-2) antigen sample using the HISCL™-5000/HISCL-800 Automated Immunoassay Systems - (PDF：170KB)
-
-
Sysmex Receives Approval for a Partial Change to the OncoGuide™ NCC Oncopanel System for Use in Cancer Genome Profiling
- Detection of 10 New Gene Mutations Including MSH6 and PMS2, NTRK3 Gene Fusion and Microsatellite Instability - (PDF：238KB)
-
-
Insurance Coverage Received for HISCL™ IFN-λ3 Assay Kit, a Test Kit to Assist in Determining Exacerbation Risk in SARS-CoV-2-Positive Patients (PDF：192KB)
-
-
Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2021 (PDF：452KB)
-
-
Sysmex and Siemens Healthineers Extend Long-standing Global Alliance in Hemostasis Testing (PDF：148KB)
-
-
Sysmex Establishes New Subsidiary in Portugal
- Increasing Portuguese Market Presence by Enhancing Sales and After-Sales Support Networks - (PDF：163KB)
-
-
Sysmex and Yamato Logistics to Commence GDP-Compliant Transport of Reagents for Gene Testing at the Ultralow Temperature Range of Minus 70 Degrees Celsius or Below
- Also Commencing Experiments for Ultralow Temperature Transport Without Using Dry Ice - (PDF：251KB)
-
-
Sysmex Selected as One of the Global 100's Most Sustainable Companies in the World for the Fourth Time (PDF：173KB)
-
-
Sysmex and Roche Renew Agreement for Global Alliance
- Transforming a long-standing alliance into one for the next generation - (PDF：145KB)
